Longeveron touts PhI­Ia Alzheimer's da­ta, but drug's fu­ture re­mains murky

Longeveron re­leased an up­date from a small Phase IIa Alzheimer’s study Thurs­day morn­ing, claim­ing to show a win at the drug’s low dose. But ques­tions re­main over its ef­fi­ca­cy at high­er dos­es and the com­pa­ny’s next steps.

In a 49-pa­tient tri­al test­ing the drug at three dif­fer­ent dose lev­els, on­ly the low­est dose achieved a pre-spec­i­fied sta­tis­ti­cal sig­nif­i­cance com­pared to place­bo af­ter 39 weeks. For their p-val­ue, Longeveron re­searchers used a two-sided al­pha of p<0.1, and the low dose came in at p=0.091, just un­der the study’s thresh­old. Re­searchers mea­sured the drug’s ef­fect us­ing the Com­pos­ite Alzheimer’s Dis­ease Score, or CADS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER